177 related articles for article (PubMed ID: 26493618)
1. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
[TBL] [Abstract][Full Text] [Related]
2. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
3. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.
Andujar P; Lecomte C; Renier A; Fleury-Feith J; Kheuang L; Daubriac J; Janin A; Jaurand MC
Carcinogenesis; 2007 Jul; 28(7):1599-605. PubMed ID: 17272307
[TBL] [Abstract][Full Text] [Related]
5. BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array.
Serio G; Pezzuto F; Marzullo A; Scattone A; Cavone D; Punzi A; Fortarezza F; Gentile M; Buonadonna AL; Barbareschi M; Vimercati L
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829357
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.
Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M
Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839
[TBL] [Abstract][Full Text] [Related]
8. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
Xi S; Huang Q; Zeng J
J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
[TBL] [Abstract][Full Text] [Related]
9. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
Hung YP; Chirieac LR
Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
[TBL] [Abstract][Full Text] [Related]
10. Mesothelioma: morphologic and immunohistochemical findings.
Churg A
Pathologie (Heidelb); 2024 Apr; ():. PubMed ID: 38568257
[TBL] [Abstract][Full Text] [Related]
11. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Tirode F; Courtiol P; Nicholson AG; Tsao MS; Tazelaar HD; Churg A; Dacic S; Roggli V; Pissaloux D; Maussion C; Moarii M; Beasley MB; Begueret H; Chapel DB; Copin MC; Gibbs AR; Klebe S; Lantuejoul S; Nabeshima K; Vignaud JM; Attanoos R; Brcic L; Capron F; Chirieac LR; Damiola F; Sequeiros R; Cazes A; Damotte D; Foulet A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Paindavoine S; Picquenot JM; Rouquette I; Sagan C; Sauter J; Thivolet F; Brevet M; Rouvier P; Travis WD; Planchard G; Weynand B; Clozel T; Wainrib G; Fernandez-Cuesta L; Pairon JC; Rusch V; Girard N
J Thorac Oncol; 2020 Jun; 15(6):1037-1053. PubMed ID: 32165206
[TBL] [Abstract][Full Text] [Related]
13. Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment.
Febres-Aldana CA; Fanaroff R; Offin M; Zauderer MG; Sauter JL; Yang SR; Ladanyi M
Annu Rev Pathol; 2024 Jan; 19():11-42. PubMed ID: 37722697
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565815
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.
Yang H; Xu D; Schmid RA; Peng RW
Ther Adv Med Oncol; 2020; 12():1758835920971421. PubMed ID: 33240401
[TBL] [Abstract][Full Text] [Related]
16. Precision Therapy for Mesothelioma: Feasibility and New Opportunities.
Dulloo S; Bzura A; Fennell DA
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067960
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of
Alnassar N; Derry JMJ; Banna GL; Gorecki DC
Transl Lung Cancer Res; 2024 Apr; 13(4):733-748. PubMed ID: 38736495
[TBL] [Abstract][Full Text] [Related]
18. ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
Bansal VV; Mitchell O; Drazer MW; Kindler HL; Turaga KK
Ann Surg Oncol; 2024 Jun; 31(6):3785-3786. PubMed ID: 38502295
[No Abstract] [Full Text] [Related]
19. Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.
Yang H; Xu D; Yang Z; Yao F; Zhao H; Schmid RA; Peng RW
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824422
[No Abstract] [Full Text] [Related]
20. Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study.
Salo SAS; Lantto E; Robinson E; Myllärniemi M; Laaksonen S; Salo JA; Rantanen T; Ilonen I
Sci Rep; 2020 Aug; 10(1):13257. PubMed ID: 32764701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
